To provide a novel compound which has S1P receptor agonistic activity, exhibits excellent immunosuppressing effect, gives less adverse side effects, and can be orally administered.
The invention provides a compound represented by general formula (I) (wherein A is a single bond, —O—, or —CH
2
—; R
1
represents a hydrogen atom or a C
1
-C
6
alkyl group, and V represents any one group selected from among the following groups (1) to (3): (1) -G
1
-, (2) -G
2
-N(R
2
)-G
3
-, and (3) a group represented by formula 2, wherein each of Z
1
and Z
2
represents a hydrogen atom or a C
1
-C
6
alkyl group, Z
3
represents a hydrogen or the like, Q represents —CH
2
—O— or the like, and Y represents a group represented by formula 3, a salt thereof, or a solvate thereof.